{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:06:54Z","timestamp":1785330414313,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["436001001"],"award-info":[{"award-number":["436001001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1520-4","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T17:13:08Z","timestamp":1519665188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Baseline autoantibody profile in rheumatoid arthritis\u00a0is associated with early treatment response but not long-term outcomes"],"prefix":"10.1186","volume":"20","author":[{"given":"Emma C.","family":"de Moel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle F. A. M.","family":"Derksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrie","family":"Stoeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leendert A.","family":"Trouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert J.","family":"Goekoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Speyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia F.","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 E. M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"1520_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75:45\u201351.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","volume":"18","author":"L Heimans","year":"2016","unstructured":"Heimans L, Akdemir G, Boer KV, Goekoop-Ruiterman YP, Molenaar ET, van Groenendael JH, et al. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Res Ther. 2016;18:23.","journal-title":"Arthritis Res Ther."},{"key":"1520_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/ard.2008.092254","volume":"68","author":"SM Kooij van der","year":"2009","unstructured":"van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and radiographic damage after 4\u00a0years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914\u201321.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR4","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/art.24661","volume":"60","author":"D Woude van der","year":"2009","unstructured":"van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60:2262\u201371.","journal-title":"Arthritis Rheum."},{"key":"1520_CR5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/annrheumdis-2011-200736","volume":"71","author":"K Wevers-de Boer","year":"2012","unstructured":"Wevers-de Boer K, Visser K, Heimans L, Ronday HK, Molenaar E, Groenendael JH, et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis. 2012;71:1472\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR6","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3899\/jrheum.140082","volume":"41","author":"L Barra","year":"2014","unstructured":"Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014;41:2361\u20139.","journal-title":"J Rheumatol."},{"key":"1520_CR7","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3899\/jrheum.150260","volume":"42","author":"J Shu","year":"2015","unstructured":"Shu J, Bykerk VP, Boire G, Haraoui B, Hitchon C, Thorne JC, et al. Missing anticitrullinated protein antibody does not affect short-term outcomes in early inflammatory arthritis: from the Canadian Early Arthritis Cohort. J Rheumatol. 2015;42:2023\u20138.","journal-title":"J Rheumatol."},{"key":"1520_CR8","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.22525","volume":"56","author":"H Dongen van","year":"2007","unstructured":"van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424\u201332.","journal-title":"Arthritis Rheum."},{"key":"1520_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-015-0536-2","volume":"17","author":"M Brink","year":"2015","unstructured":"Brink M, Verheul MK, Ronnelid J, Berglin E, Holmdahl R, Toes RE, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015;17:25.","journal-title":"Arthritis Res Ther."},{"key":"1520_CR10","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011;108:17372\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1520_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis. 2016;75:1099\u2013107.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR12","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/art.23763","volume":"58","author":"A Ioan-Facsinay","year":"2008","unstructured":"Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008;58:3000\u20138.","journal-title":"Arthritis Rheum."},{"key":"1520_CR13","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/ard.2008.091355","volume":"68","author":"O Snir","year":"2009","unstructured":"Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis. 2009;68:736\u201343.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2017.02.008","volume":"80","author":"MK Verheul","year":"2017","unstructured":"Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, et al. Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. J Autoimmun. 2017;80:77\u201384.","journal-title":"J Autoimmun."},{"key":"1520_CR15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","volume":"73","author":"J Shi","year":"2014","unstructured":"Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780\u20133.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR16","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/ard.2009.124537","volume":"69","author":"D Woude van der","year":"2010","unstructured":"van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010;69:1554\u201361.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR17","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1002\/art.22279","volume":"54","author":"KN Verpoort","year":"2006","unstructured":"Verpoort KN, der Jol-van Zijde CM, der Papendrecht-van Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006;54:3799\u2013808.","journal-title":"Arthritis Rheum."},{"key":"1520_CR18","doi-asserted-by":"crossref","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u2013977.","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"1520_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75:16\u201322.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","volume":"75","author":"S Ajeganova","year":"2016","unstructured":"Ajeganova S, van Steenbergen HW, van Nies JA, Burgers LE, Huizinga TW, van der Helm-van Mil AH. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016;75:867\u201373.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR21","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/rheumatology\/ker516","volume":"51","author":"D Woude van der","year":"2012","unstructured":"van der Woude D, Visser K, Klarenbeek NB, Ronday HK, Peeters AJ, Kerstens PJ, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012;51:1120\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1520_CR22","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1002\/art.23127","volume":"56","author":"KN Verpoort","year":"2007","unstructured":"Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-Bouwstra JK, Allaart CF, et al. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum. 2007;56:3949\u201352.","journal-title":"Arthritis Rheum."},{"key":"1520_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-017-1392-z","volume":"19","author":"MAM Delft van","year":"2017","unstructured":"van Delft MAM, Verheul MK, Burgers LE, Derksen V, van der Helm-van Mil AHM, van der Woude D, et al. The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Arthritis Res Ther. 2017;19:190.","journal-title":"Arthritis Res Ther."},{"key":"1520_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/art.30409","volume":"63","author":"A Willemze","year":"2011","unstructured":"Willemze A, van der Woude D, Ghidey W, Levarht EW, Stoeken-Rijsbergen G, Verduyn W, et al. The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis Rheum. 2011;63:1823\u201332.","journal-title":"Arthritis Rheum."},{"key":"1520_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13317-010-0013-5","volume":"1","author":"M Fabris","year":"2010","unstructured":"Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, et al. Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights. 2010;1:87\u201394.","journal-title":"Auto Immun Highlights."},{"key":"1520_CR26","doi-asserted-by":"publisher","first-page":"e40362","DOI":"10.1371\/journal.pone.0040362","volume":"7","author":"G Ferraccioli","year":"2012","unstructured":"Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7:e40362.","journal-title":"PLoS One."},{"key":"1520_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","volume":"76","author":"CP Figueiredo","year":"2017","unstructured":"Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, et al. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann Rheum Dis. 2017;76:399\u2013407.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/annrheumdis-2014-207182","volume":"75","author":"PF Kerkman","year":"2016","unstructured":"Kerkman PF, Fabre E, van der Voort EI, Zaldumbide A, Rombouts Y, Rispens T, et al. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1170\u20136.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-202893","volume":"72","author":"PF Kerkman","year":"2013","unstructured":"Kerkman PF, Rombouts Y, van der Voort EI, Trouw LA, Huizinga TW, Toes RE, et al. Circulating plasmablasts\/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1259\u201363.","journal-title":"Ann Rheum Dis."},{"key":"1520_CR30","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/art.40053","volume":"69","author":"AJ Pelzek","year":"2017","unstructured":"Pelzek AJ, Gronwall C, Rosenthal P, Greenberg JD, McGeachy M, Moreland L, et al. Disease associated anti-citrullinated protein memory B cells in rheumatoid arthritis persist in clinical remission. Arthritis Rheumatol. 2017;69:1176\u201386.","journal-title":"Arthritis Rheumatol."},{"key":"1520_CR31","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jclinepi.2006.02.007","volume":"59","author":"GJ Breukelen Van","year":"2006","unstructured":"Van Breukelen GJ. ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol. 2006;59:920\u20135.","journal-title":"J Clin Epidemiol."},{"key":"1520_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13075-015-0860-6","volume":"17","author":"J Shi","year":"2015","unstructured":"Shi J, van Steenbergen HW, van Nies JA, Levarht EW, Huizinga TW, van der Helm-van Mil AH, et al. The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res Ther. 2015;17:339.","journal-title":"Arthritis Res Ther."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1520-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T18:07:55Z","timestamp":1570817275000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1520-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1520-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"24 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted with the approval of the regional ethics committee at Leiden University Medical Center. The IMPROVED study was approved by the Medical Ethics Committees of all participating hospitals. Informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"33"}}